Research progress on application of drug nano-carriers

Yaoxue Xuebao

Volumn 38, Issue 3, 2003, Pages 236-240

  Wen, Tao ^a   Jia, Tao ^b   Wang, Yi Ming ^a   Luo, Guo An ^a  

^a TSINGHUA UNIVERSITY   (China)

^b Beijing Technology and Commerce University   (China)

Author keywords

Controlling releasing; Drug carrier; Nano; Targeting delivery

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG CARRIER; GROWTH HORMONE RELEASING FACTOR;

ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; NANOTECHNOLOGY; RESEARCH; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GROWTH HORMONE-RELEASING HORMONE; NANOTECHNOLOGY; RESEARCH;

EID: 2142799557     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Torchilin, Vladimir P. Drug targeting [J]. Eur J Pharm Sci, 2000,11(2):81-91.
2. Thompson WW, Anderson DB, Heiman ML. Biodegradable microspheres as a delivery system for rismorelin porcine, a porcine-growth-hormone-releasing- hormone [J]. J Controlled Release, 1997,43(1):9-22.
3. Foster TP, Moseley WM, Caputo JF, et al. Sustained elevated serum somatotropin concentrations in Holstein steers following subcutaneous delivery of a growth hormone releasing factor analog dispersed in water, oil or microspheres [J]. J Controlled Release, 1997,47(1):91-99.
4. Damge C, Hillairebuys D, Puech R, et al. Effects of orally-administered insulin nanocapsules in normal and diabetic dogs [J]. Diabetes Nutr Metab, 1995,8(1):3-9.
5. Lamprecht A, Schafer U, Lehr CM. Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa [J]. Pharm Res, 2001,18(6):788-793.
6. Chavany C, Connell Y, Neckers L. Contribution of sequence and phosphorothioate content to inhibition of cell-growth and adhesion caused by c-myc antisense oligomers [J]. Mol Pharmacol, 1995,48(4):738-746.
7. Fritz H, Maier M, Bayer E. Cationic polystyrene nanoparticles: preparation and characterization of a model drug carrier system for antisense oligonucleotides [J]. J Colloid Interface Sci, 1997,195(2):272- 288.
8. Godard G, Boutorine AS, Saisonbehmoaras E, et al. Anti-sense effects of cholesterol-oligodeoxynucleotide conjugates associated with poly (alkylcyanoacrylate) nanoparticles [J]. Eur J Biochem, 1995,232(2):404-410.
9. Nakada Y, Fattal E, Foulquier M, et al. Pharmacokinetics and biodistribution of oligonucleotide adsorbed onto poly (isobutylcyanoacrylate) nanoparticles after intravenous administration in mice [J]. Pharm Res, 1996,13(1):38-43.
10. Morin C, Barratt G, Fessi H, et al. Improved intracellular delivery of a muramyl dipeptide analog by means of nanocapsules [J]. Int J Immunopharmacol, 1994,16(5-6):451-456.
11. Barratt G, Puisieux F, Yu WP, et al. Antimetastatic activity of mdp-1-alanyl-cholesterol incorporated into various types of nanocapsules [J]. Int J Immunopharmacol, 1994,16(5-6):457-461.
12. Allemann E, Brasseur N, Benrezzak O, et al. Peg-coated poly (lactic acid) nanoparticles for the delivery of hexadecafluoro zinc phthalocyanine to emt-6 mouse mammary-tumors [J]. J Pharm Pharmacol, 1995,47(5):382-387.
13. Sharma D, Chelvi TP, Kaur J, et al. Novel taxol (R) formulation: polyvinylpyrrolidone nanoparticle-encapsulated taxol (R) for drug delivery in cancer therapy [J]. Oncol Res, 1996,8(7-8):281-286.
14. Leroux JC, Cozens R, Roesel JL, et al. Pharmacokinetics of a novel hiv-1 protease inhibitor incorporated into biodegradable or enteric nanoparticles following intravenous and oral-administration to mice [J]. J Pharm Sci, 1995,84(12):1387-1391.
15. Lobenberg R, Kreuter J. Macrophage targeting of azidothymidine: a promising strategy for AIDS therapy [J]. Aids Res Hum Retrov, 1996,12(18):1709-1715.
16. Rodrigues JM, Croft SL, Fessi H, et al. The activity and ultrastructural-localization of primaquine-loaded poly (d, l- lactide) nanoparticles in leishmania-donovani infected mice [J]. Trop Med Parasitol, 1994,45(3):223-228.
17. Karajgi JS, Vyas SP. A lymphotropic colloidal carrier system for diethylcarbamazine-preparation and performance evaluation [J]. J Microencapsul, 1994,11(5):539-545.
18. Fresta M, Puglisi G, Giammona G, et al. Pefloxaeine mesilate-loaded and ofloxacin-loaded polyethylcyanoacrylate nanoparticles- characterization of the colloidal drug carrier formulation [J]. J Pharm Sci, 1995,84(7):895-902.
19. Kreuter J. Nanoparticles and microparticles for drug and vaccine delivery [J]. J Anat, 1996,189(3):503-505.
20. O'Hagan DT. Microparticles and polymers for the mucosal delivery of vaccines [J]. Adv Drug Deliv Rev, 1998,34(2-3):305-320.
21. Kossovsky N, Gelman A, Hnatyszyn HJ, et al. Surface-modified diamond nanoparticles as antigen delivery vehicles [J]. Bioconjugate Chem, 1995,6(5):507-511.
22. Bergemann C, Müller-Schulte D, Oster J, et al. Magnetic ion-exchange nano- and microparticles for medical, biochemical and molecular biological applications [J]. Magn Magn Mater, 1999,194(1-3):45-52.
23. Flicker J. Drugs with a magnetic attraction to tumours [J]. Drug Discovery Today, 2001,6(8):387-389.
24. Ferranti V, Marchais H, Chabenat C, et al. Primidone-loaded poly-epsilon-eaprolactone nanocapsules: incorporation efficiency and in vitro release profiles [J]. Int J Pharm, 1999,193(1):107-111.
25. Zimmer A, Mutschler E, Lambrecht G, et al. Pharmacokinetic and pharmacodynamic aspects of an ophthalmic pilocarpine nanoparticle-delivery- system [J]. Pharmaceut Res, 1994,11(10):1435-1442.
26. Calvo P, Vilajato JL, Alonso MJ. Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers [J]. Int J Pharm, 1997,153(1):41-50.
27. Allemann E, Leroux JC, Gurny R, et al. In vitro extended-release properties of drug-loaded poly (dl-lactic acid) nanoparticles produced by a salting-out procedure [J]. Pharm Res, 1993,10(12):1732-1737.
28. Schroder U, Sabel BA. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of iv dalargin injections [J]. Brain Res, 1996,710(1-2):121-124.
29. Alyautdin RN, Petrov VE, Langer K, et al. Delivery of loperamide across the blood-brain barrier widi polysorbate 80-coated polybutylcyanoacrylate nanoparticles [J]. Pharm Res, 1997,14(3):325-328.
30. Polato L, Benedetti LM, Callegaro L, et al. In vitro evaluation of nanoparticle formulations containing gangliosides [J]. J Drug Target, 1994,2(1):53-59.
31. Kim YI, Fluckiger L, Hoffman M, et al. The antihypertensive effect of orally administered nifedipine-loaded nanoparticles in spontaneously hypertensive rats [J]. Brit J Pharmacol, 1997,120(3):399-404.
32. Labhasetwar V, Song CX, Humphrey W, et al. Arterial uptake of biodegradable nanoparticles: effect of surface modifications [J]. J Pharm Sci, 1998,87(10):1229-1234.